TKI Plus Checkpoint Inhibitor Without Chemotherapy Shows Promise as Initial Option in Advanced NSCLC

Co-mutations in DNA Damage-Response Pathways May Predict Effectiveness of Checkpoint Inhibitors in NSCLC

Translating Early Research to Adapt CAR T-Cell Therapy to Solid Tumors

Pembrolizumab Considered for Second Tissue-Agnostic Cancer Indication

New FDA Commissioner Confirmed

Dr. Richard Pazdur Discusses Project Facilitate and the Expanded-Access Program

NCI Director Dr. Norman E. Sharpless Discusses 2019 Budget Plans During Social Media Event

FDA Approval Processes in the Era of Targeted Therapies: A Conversation with Dr. Richard Pazdur

NCI Corner: Racial Differences in the Transcriptomes of Lung Tumors

NCI Selects Five Teams of Researchers to Expand Discovery of Predictive Biomarkers for Immunotherapy

The Budget Landscape with Dr. Douglas R. Lowy

FDA Fosters Understanding about Approval Process for Biosimilars